Patents by Inventor Ryan Faucette

Ryan Faucette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20240142468
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: October 4, 2023
    Publication date: May 2, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • RNA biomarkers for hereditary angioedema
    Patent number: 11884979
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) ANDCLEAVED HMWK
    Publication number: 20230408528
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
    Patent number: 11826758
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: November 28, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Protein biomarkers for diseases associated with the contact activation system
    Patent number: 11815516
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 14, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
    Publication number: 20230182139
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: August 23, 2022
    Publication date: June 15, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
    Patent number: 11668718
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 6, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20220365101
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
    Patent number: 11458477
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Assays for determining plasma kallikrein system biomarkers
    Patent number: 11372002
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
    Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Metabolite biomarkers for diseases associated with the contact activation system
    Patent number: 11340237
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 24, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • Methods of determining levels of cleaved and/or intact kininogen
    Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
    Publication number: 20210322972
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 21, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • PROTEIN BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20210285962
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: September 15, 2017
    Publication date: September 16, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • IMMUNOASSAY TO DETECT CLEAVED HIGH MOLECULAR WEIGHT KININOGEN
    Publication number: 20210270842
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
    Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20210087293
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Immunoassay to detect cleaved high molecular weight kininogen
    Patent number: 10914747
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic